Novo Nordisk (NVO) - Share Chat

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide

They’re the top producer in diabetic care, hoping to see this in the 250 US batch!



Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products.

The company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. Products marketed to over 180 countries.

I opened a position in NVO earlier this month on the back of a post-earnings decline.

I like its core diabetes business and I’m optimistic about the potential of its weight-loss drugs.

As the Barron’s article below points out, this could be an annual trillion dollar market in the US – if insurers can be persuaded to pay for it on a preventative basis.

I might be a bit late to the party here, but after the UK have authorised the use of Novos’ weight loss inj, I’m hoping for a little extra return on my investment. I think this will hype up quite rapidly. *disclaimer - I am not a seasoned trader, so please do your own research!

Just jumped on my watchlist after this news.

Seems to be doing big things with both obesity and diabetes.


This is relatively big news for Novo Nordisk. T’other day, I read that NVO briefly became Europe’s most valuable company over LVMH. It’s marketcap has also inched ahead of Denmark’s yearly GDP. :exploding_head:


This company seems to be doing quite well with its focus on weight loss drugs that are now coming into the market.


Shameless plug here @Eden but i did a video on it 4 months ago covering Wegovy / Semaglutide and the global ‘obesity’ market if interested:

Probably going to be big business!!! My background is biomedical sciences :sunglasses::+1:


Great breakdown and analysis. Thank you.

Fantastic production too, very professional :clap:

1 Like